$0.15
5.00% day before yesterday
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US86664M2061
Symbol
PBLA

Panbela Therapeutics Inc Stock price

$0.15
-0.01 5.00% 1M
-0.19 56.02% 6M
-0.23 60.53% YTD
-0.19 56.24% 1Y
-17,039.85 100.00% 3Y
-59,800.65 100.00% 5Y
-2.85 95.00% 10Y
-0.40 72.73% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.00 0.00%
ISIN
US86664M2061
Symbol
PBLA
Industry

Key metrics

Basic
Market capitalization
$730.0k
Enterprise Value
$7.0m
Net debt
$6.3m
Cash
$140.0k
Shares outstanding
4.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-39.9%
Return on Equity
536.4%
ROCE
238.9%
ROIC
-
Debt/Equity
-0.4
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-28.2m
EBIT
$-35.8m | $-27.5m
Net Income
$-35.0m | $-26.5m
Free Cash Flow
$-15.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-50.4% | -7.0%
Net Income
-48.9% | -5.0%
Free Cash Flow
42.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-7.2
FCF per Share
$-3.2
Short interest
3.1%
Employees
8
Rev per Employee
$0.0
Show more

Is Panbela Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Panbela Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Panbela Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Panbela Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Panbela Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.56 5.56
4% 4%
-
- Research and Development Expense 30 30
68% 68%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -36 -36
50% 50%
-
Net Profit -35 -35
49% 49%
-

In millions USD.

Don't miss a Thing! We will send you all news about Panbela Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The company was founded by Michael Cullen and Thomas Neenan on September 21, 2011 and is headquartered in Waconia, MN.

Head office United States
CEO Jennifer Simpson
Employees 8
Founded 2011
Website panbela.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today